But there appears to be only one new cholesterol-lowering pill in mid-stage development, and its a drug that Pfizer ate up and spit out.

FORBES: As Companies Abandon Cholesterol, An Old Player Re-Emerges

However, the service only plans to select one team to go forward to the next stage of development, and that one team will likely dominate the electronic-warfare business for decades to come.

FORBES: Outcome Of Three Programs Will Drive Defense Sector Consolidation

Drug development is a risky business, where one-fifth of the compounds that enter late-stage trials fail.

FORBES: Three Losers